BACKGROUND: In this report, we examine the surgical safety and complications (SC) among 125 liver (L) and 150 kidney (K) HIV+ transplantation (TX) recipients in a prospective nonrandomized U.S. multicenter trial. METHODS: Subjects were required to have CD4+ T-cell counts >200/100 cells/mm3 (K/L) and undetectable plasma HIV-1 RNA (Viral Load [VL]) (K) or expected posttransplantation suppression (L). Impact of SCs (N ≥ 7) was evaluated by use of the proportional hazards models. Baseline morbidity predictors for SCs (N ≥ 7) were assessed in univariate proportional hazards models. RESULTS: At median 2.7 (interquartile range 1.9-4.1) and 2.3 (1.0-3.7) years after TX, 3-month and 1-year graft survival were [K] 96% (95% CI 91%-98%) and 91% (95% CI 85%-94%) and [L] 91% (95% CI 85%-95%) and 77% (95% CI 69%-84%), respectively. A total of 14 K and 28 L graft losses occurred in the first year; 6 K and 11 L were in the first 3 months. A total of 26 (17%) K and 43 (34%) L experienced 29 and 62 SCs, respectively. In the liver multivariate model, re-exploration was marginally associated (hazard ratio [HR] 2.8; 95% CI 1.0-8.4; P = .06) with increased risk of graft loss, whereas a greater MELD score before transplantation (HR 1.07 per point increase; 95% CI: 1.01-1.14; P = .02), and detectable viral load before TX (HR 3.6; 95% CI 0.9-14.6; P = .07) was associated with an increased risk of wound infections/dehiscence. CONCLUSION: The rates and outcomes of surgical complications are similar to what has been observed in the non-HIV setting in carefully selected HIV-infected liver and kidney TX recipients.
BACKGROUND: In this report, we examine the surgical safety and complications (SC) among 125 liver (L) and 150 kidney (K) HIV+ transplantation (TX) recipients in a prospective nonrandomized U.S. multicenter trial. METHODS: Subjects were required to have CD4+ T-cell counts >200/100 cells/mm3 (K/L) and undetectable plasma HIV-1 RNA (Viral Load [VL]) (K) or expected posttransplantation suppression (L). Impact of SCs (N ≥ 7) was evaluated by use of the proportional hazards models. Baseline morbidity predictors for SCs (N ≥ 7) were assessed in univariate proportional hazards models. RESULTS: At median 2.7 (interquartile range 1.9-4.1) and 2.3 (1.0-3.7) years after TX, 3-month and 1-year graft survival were [K] 96% (95% CI 91%-98%) and 91% (95% CI 85%-94%) and [L] 91% (95% CI 85%-95%) and 77% (95% CI 69%-84%), respectively. A total of 14 K and 28 L graft losses occurred in the first year; 6 K and 11 L were in the first 3 months. A total of 26 (17%) K and 43 (34%) L experienced 29 and 62 SCs, respectively. In the liver multivariate model, re-exploration was marginally associated (hazard ratio [HR] 2.8; 95% CI 1.0-8.4; P = .06) with increased risk of graft loss, whereas a greater MELD score before transplantation (HR 1.07 per point increase; 95% CI: 1.01-1.14; P = .02), and detectable viral load before TX (HR 3.6; 95% CI 0.9-14.6; P = .07) was associated with an increased risk of wound infections/dehiscence. CONCLUSION: The rates and outcomes of surgical complications are similar to what has been observed in the non-HIV setting in carefully selected HIV-infected liver and kidney TX recipients.
Authors: Ania Lucewicz; Germaine Wong; Vincent W T Lam; Wayne J Hawthorne; Richard Allen; Jonathan C Craig; Henry C C Pleass Journal: Transplantation Date: 2011-09-27 Impact factor: 4.939
Authors: Hamid R Davari; Hooman Yarmohammadi; Seyed A Malekhosseini; Heshmatollah Salahi; Ali Bahador; Mehdi Salehipour Journal: Int J Urol Date: 2006-10 Impact factor: 3.369
Authors: F J Palella; K M Delaney; A C Moorman; M O Loveless; J Fuhrer; G A Satten; D J Aschman; S D Holmberg Journal: N Engl J Med Date: 1998-03-26 Impact factor: 91.245
Authors: Peter G Stock; Burc Barin; Barbara Murphy; Douglas Hanto; Jorge M Diego; Jimmy Light; Charles Davis; Emily Blumberg; David Simon; Aruna Subramanian; J Michael Millis; G Marshall Lyon; Kenneth Brayman; Doug Slakey; Ron Shapiro; Joseph Melancon; Jeffrey M Jacobson; Valentina Stosor; Jean L Olson; Donald M Stablein; Michelle E Roland Journal: N Engl J Med Date: 2010-11-18 Impact factor: 91.245
Authors: Piotr Kaliciński; Małgorzata Markiewicz; Andrzej Kamiński; Przemysław Laniewski; Hor Ismail; Tomasz Drewniak; Marek Szymczak; Paweł Nachulewicz; Elzbieta Jezierska Journal: Pediatr Transplant Date: 2005-06
Authors: Guy W Neff; Andrew Bonham; Andreas G Tzakis; Margaret Ragni; Dushyantha Jayaweera; Eugene R Schiff; Obaid Shakil; John J Fung Journal: Liver Transpl Date: 2003-03 Impact factor: 5.799
Authors: M E Roland; B Barin; L Carlson; L A Frassetto; N A Terrault; R Hirose; C E Freise; L Z Benet; N L Ascher; J P Roberts; B Murphy; M J Keller; K M Olthoff; E A Blumberg; K L Brayman; S T Bartlett; C E Davis; J M McCune; B M Bredt; D M Stablein; P G Stock Journal: Am J Transplant Date: 2007-12-18 Impact factor: 8.086
Authors: Joseph T King; Melissa F Perkal; Ronnie A Rosenthal; Adam J Gordon; Stephen Crystal; Maria C Rodriguez-Barradas; Adeel A Butt; Cynthia L Gibert; David Rimland; Michael S Simberkoff; Amy C Justice Journal: JAMA Surg Date: 2015-04 Impact factor: 14.766
Authors: L M Kucirka; C M Durand; S Bae; R K Avery; J E Locke; B J Orandi; M McAdams-DeMarco; M E Grams; D L Segev Journal: Am J Transplant Date: 2016-05-25 Impact factor: 8.086
Authors: Elmi Muller; Francois C J Botha; Zunaid A Barday; Kathryn Manning; Peter Chin-Hong; Peter Stock Journal: Transplantation Date: 2021-07-01 Impact factor: 5.385
Authors: Clara Tan-Tam; Pamela Liao; Julio S Montaner; Mark W Hull; Charles H Scudamore; Siegfried R Erb; Eric M Yoshida Journal: Can J Infect Dis Med Microbiol Date: 2014-05 Impact factor: 2.471